OPEN END TURBO BULL - VERTEX PHARMACEUTICALS | Market Closed - Boerse Frankfurt Warrants 01:33:11 2024-06-14 pm EDT | ||
| 14.48 EUR | +2.70% |
|
| Current month | +26.80% | ||
| 1 month | +58.42% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 14.48 | +2.70% |
| 24-06-13 | 14.1 | +2.10% |
| 24-06-12 | 13.81 | -3.16% |
| 24-06-11 | 14.26 | -0.35% |
| 24-06-10 | 14.31 | -1.24% |
Real-time Boerse Frankfurt Warrants
Last update June 14, 2024 at 01:33 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Citi
|
| WKN | KH4824 |
| ISIN | DE000KH48240 |
| Date issued | 2023-03-27 |
| Strike | 331.8 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.02 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 14.66 € |
|---|---|
| Lowest since issue | 1.42 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
480.7
USD
Average target price
463.4
USD
Spread / Average Target
-3.60%
- Stock Market
- Certificates
- Certificat
